Altamira Therapeutics Ltd Stock Price, News & Analysis

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced a marketing agreement with Avernus Pharma Ltd. to distribute its nasal spray, Bentrio, in several Gulf countries. The product aims to protect against airborne viruses and allergens. Bentrio demonstrated a more than 99% reduction in SARS-CoV-2 viral load in laboratory tests and alleviated allergic rhinitis symptoms. Sales in the region are projected to begin in 2022 following regulatory approvals. This collaboration leverages Avernus' strong distribution network in the Middle East.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has announced the formation of a new business unit, OTC Consumer Health, aimed at enhancing its global roll-out of Bentrio™, a nasal spray that protects against airborne viruses and allergens. This unit will be led by Jean Lachance, an experienced marketing strategist with over 20 years in the OTC consumer health sector. His leadership is expected to drive growth for Bentrio in 2022 and beyond.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced the approval of its nasal spray, Bentrio™, by the Medical Device Authority of Malaysia, allowing for commercialization in the country. This follows previous clearance in Singapore, with Wellesta Holdings Pte Ltd set to manage distribution across several Asian markets, including India and Indonesia. CEO Thomas Meyer expressed optimism about Bentrio contributing significantly to revenue in 2022 as they aim to protect consumers from airborne allergens and viruses.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has appointed Covadonga Pañeda, Ph.D., as Chief Development Officer, enhancing its leadership team focused on RNA therapeutics. Effective April 2022, Dr. Pañeda will supervise the development of the company’s OligoPhore and SemaPhore platforms for RNA delivery. Additionally, the company received a Small Business Technology Transfer (STTR) grant from the NIH to advance its siRNA delivery technology aimed at treating inflammatory disorders, targeting diseases beyond the liver.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced that its Chairman and CEO, Thomas Meyer, will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 AM ET on the conference portal and the company's website under 'Events and Presentations' in the 'Investors & Media' section. Altamira focuses on RNA therapeutics, viral infection protection, and inner ear therapeutics, with several products in various stages of development, including AM-125 for vertigo and Keyzilen for tinnitus.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has announced significant advancements regarding Bentrio™, its nasal spray designed for protection against airborne viruses and allergens. The product is now available on Amazon in Germany and has secured distribution agreements covering six Asian countries. Clinical trials for Bentrio™ against COVID-19 and allergy-related conditions are in progress, with results expected in the first half of 2022. The company is also preparing to evaluate Bentrio™ against the Omicron variant.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has randomized the first group of patients in a clinical trial for Bentrio (AM-301), aimed at treating house dust mite allergic rhinitis. The trial will enroll 36 patients, assessing the efficacy of the drug-free nasal spray against perennial allergic rhinitis under controlled exposure. Top-line results are expected by spring. Bentrio is currently marketed in various countries and aims to provide relief from airborne allergens and viruses, making it a viable option for allergy sufferers worldwide.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has initiated the NASAR trial, randomizing its first patient to evaluate the Bentrio™ (AM-301) nasal spray for seasonal allergic rhinitis (SAR). The trial will involve 100 patients and compare Bentrio™'s efficacy and safety against a saline spray over two weeks. Conducted during the pollen season in Australia, it aims to assess Bentrio™'s protective effects against airborne allergens. This follows positive results from earlier studies indicating rapid and durable effects against allergic rhinitis.

Altamira Therapeutics (NASDAQ:CYTO) announced promising results from two studies on RNA delivery platforms for treating abdominal aortic aneurysm (AAA) at the AHA Scientific Sessions 2021. The studies demonstrated that siRNA polyplexes targeting NF-kB significantly reduced AAA progression and aorta rupture, protecting 100% of mice in trials. Additionally, mRNA polyplexes targeting SOD-2 helped mitigate aneurysm expansion. These findings emphasize the potential of Altamira's delivery technologies for addressing AAA, a condition with high mortality rates if untreated.